Radi, G.; Simonetti, O.; Rizzetto, G.; Diotallevi, F.; Molinelli, E.; Offidani, A.
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients. Healthcare 2021, 9, 1575.
https://doi.org/10.3390/healthcare9111575
AMA Style
Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A.
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients. Healthcare. 2021; 9(11):1575.
https://doi.org/10.3390/healthcare9111575
Chicago/Turabian Style
Radi, Giulia, Oriana Simonetti, Giulio Rizzetto, Federico Diotallevi, Elisa Molinelli, and Annamaria Offidani.
2021. "Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients" Healthcare 9, no. 11: 1575.
https://doi.org/10.3390/healthcare9111575
APA Style
Radi, G., Simonetti, O., Rizzetto, G., Diotallevi, F., Molinelli, E., & Offidani, A.
(2021). Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients. Healthcare, 9(11), 1575.
https://doi.org/10.3390/healthcare9111575